Sign in
Taking peopleNo phase

Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage

Key facts

Who runs it
Southwest Hospital, China
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
280 people, planned
Started
1 Jun 2025
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • neuroendoscopic surgery
  • craniotomy
Record updated
18 May 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age 18-80 years old, male or female
  • The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used)
  • Patients with supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage (supratentorial intracerebral hemorrhage) whose hematoma volume is ≥50ml or whose hematoma produces obvious space occupying effect and requires emergency surgery (including patients with cerebral hernia signs such as retarding or dilatation of light reflex of one pupil)
  • Before randomization, GCS score was 5-14, NIHSS score was ≥6
  • mRS Before onset: 0-1 score
  • Randomization within 24 hours after the first diagnostic CT
  • The patient or family members are informed and voluntarily sign the informed consent

Who cannot take part

  • Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery
  • The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc
  • Thalamic hemorrhage, primary ventricular hemorrhage
  • Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points
  • Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days
  • Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required
  • Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems
  • Platelet count <100×109/L, INR > 1.4
  • Pregnant or breastfeeding women, or those who expect to become pregnant within one year
  • are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and/or epidemiological studies)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.

The 2 groups in the trial

  • Experimental ArmTreatment being tested

    Neuroendoscopic Surgery to remove intracranial hematoma

    Treatment: neuroendoscopic surgery

  • Control ArmExisting treatment, for comparison

    Craniotomy to remove intracranial hematoma

    Treatment: craniotomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage: a Multicenter, Randomized, Controlled Clinical Trial
Criteria questions
Built from NCT06894433, who can take part
Record updated
18 May 2025